Trevena (TRVN) to Offer Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/1/2026
- Wall Street ends higher as Amazon soothes AI jitters
- Amazon shares rally as cloud growth surges and spending outlook climbs
- Apple shares sink on disappointing September quarter sales outlook
- Novo Nordisk stock tumbles 10% as key trial misses goal
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- SCYNEXIS (SCYX) Move Attributed to Morning Note from Brookline
- AbbVie (ABBV) Misses Q2 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance
- Short sellers pile into SpaceX ahead of earnings, lockup expiration
- Wall Street ends higher as Amazon soothes AI jitters
- Novo Nordisk's ziltivekimab fails to reduce heart risk in ZEUS trial
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
Trevena Announces Proposed Public Offering of Common Stock
August 11, 2020 4:01 PM EDTCHESTERBROOK, Pa., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. In addition, Trevena intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. The offering is subject to market conditions, and... More
